fbpx
QQQ
+ 0.40
341.21
+ 0.12%
DIA
+ 1.41
339.04
+ 0.41%
SPY
+ 1.40
414.50
+ 0.34%
TLT
-1.09
141.44
-0.78%
GLD
+ 1.00
164.35
+ 0.6%

Why Gritstone Oncology's Stock is Trading Higher Today

January 20, 2021 9:53 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Gritstone Oncology's Stock Price And Volume Action

Gritstone Oncology (NASDAQ:GRTS) is currently up 6.87% to a price of $21.46. The stock's volume is currently 2.72 million, which is roughly 83.78% of its recent 30-day volume average of 3.24 million.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Gritstone Oncology shares were trading higher after the company announced an agreement with Genevant to obtain a nonexclusive license to Genevant's LNP technology to develop and commercialize self-amplifying RNA vaccines against COVID-19.

Insights On Recent Price Action

The moving average price of the stock over the past 50 days was $3.98 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $22.47 and as low as $2.54.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.

Posted-In:

Movers Trading Ideas

Related Articles

12 Health Care Stocks Moving In Tuesday's Intraday Session

  read more

60 Biggest Movers From Yesterday

Gainers Olink Holding AB (NASDAQ: OLK) shares surged 80% to close at $36.00 on Thursday after the company priced its IPO at $20 per share. read more

42 Stocks Moving In Thursday's Mid-Day Session

Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) climbed 64.2% to $5.73. Cellect Biotechnology and Quoin Pharmaceuticals reported a strategic merger. read more

38 Stocks Moving in Tuesday's Pre-Market Session

Gainers Artelo Biosciences, Inc. (NASDAQ: ARTL) shares rose 126.9% to $2.36 in pre-market trading after climbing over 8% on Monday. The company, last month, reported upbeat Q1 earnings. read more